December 09, 2023
A former BigLaw partner in his 30s made history by joining a preeminent circuit court, a former BigLaw partner in his 50s made waves by leaving the largest circuit, and a former chemist in her 90s made enemies by resisting a probe on the most specialized circuit. That's a small sample of the intrigue that flourished in 2023 throughout the federal appellate system, where diversity bloomed and controversy abounded.
August 16, 2023
The Fifth Circuit on Wednesday rejected an extraordinary decision blocking the U.S. Food and Drug Administration's decades-old approval of the widely used abortion medication mifepristone, but also upheld the decision's reinstatement of restrictions on access to the medication.
July 21, 2023
A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.
July 05, 2023
A challenge to a decades-old decision by the U.S. Food and Drug Administration to approve an abortion drug has ramifications for product liability cases involving federal agency decisions, and the first talc trial since Johnson & Johnson placed a subsidiary in bankruptcy may influence whether other claimants opt to accept an $8.9 billion settlement.Â
June 23, 2023
A year after the U.S. Supreme Court handed down a bombshell ruling that erased the constitutional right to abortion, employers that want to preserve access to the procedure for their workers are still unsure about the legal landscape. Here are three questions benefits attorneys are asking on the anniversary of the high court's Dobbs decision.
June 22, 2023
The U.S. Supreme Court's elimination of the constitutional right to abortion hit like an earthquake last summer, uprooting long-standing reproductive rights, triggering state laws curbing abortion access and flooding courts with litigation. A year later, legal battles promise further shake-ups to the abortion landscape.
May 17, 2023
A Fifth Circuit panel peppered the U.S. Food and Drug Administration with questions Wednesday during oral arguments about the approval the agency gave decades ago to a now widely used abortion medication, while also picking apart the arguments of anti-abortion physicians who claim they face imminent harm by the drug's approval.
May 15, 2023
Merely being opposed to abortion does not give certain groups the right to sue the U.S. Food and Drug Administration over its decades-old approval of mifepristone, the federal government has told the Fifth Circuit, warning that allowing such a theory to prevail would dramatically expand Article III standing.
May 09, 2023
Anti-abortion groups challenging the U.S. Food and Drug Administration's approval of mifepristone in 2000 slammed the agency's allegedly "decades-long pattern of delay and obfuscation" and urged the Fifth Circuit to uphold a Texas ruling that would have blocked access to the common abortifacient last month had the U.S. Supreme Court not intervened.
May 03, 2023
Former officials of the U.S. Food and Drug Administration and U.S. Department of Justice, along with more than 250 members of Congress, have backed the federal government's challenge at the Fifth Circuit to a Texas federal court decision that blocked access to a common abortion medication.